ElevateBio logo

ElevateBio Funding & Investors

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

elevate.bio

Total Amount Raised: $1,246,000,000

ElevateBio Funding Rounds

  • Series D

    $401,000,000

    Series D Investors

    Matrix Capital Management
    Redmile Group
    MPM Capital
    SoftBank Vision Fund
    F2 Ventures
    Woodline Partners
    Invus
    Novo Nordisk
    Fidelity Investments
    Emerson Collective
    Surveyor Capital
    EcoR1 Capital
    Samsara BioCapital
    Vertex Holdings
    EDBI
    ITOCHU
    Lee Family Office
  • Series C

    $525,000,000

    Series C Investors

    Matrix Capital Management
    EcoR1 Capital
    MPM Capital
    SoftBank Vision Fund
    F2 Ventures
    Invus
    Fidelity Investments
    Vertex Holdings
    Redmile Group
    ITOCHU
    Surveyor Capital
    Samsara BioCapital
    Emerson Collective
    EDBI
  • Series B

    $170,000,000

    Series B Investors

    EDBI
    Samsara BioCapital
    Invus
    F2 Ventures
    Redmile Group
    MPM Capital
    EcoR1 Capital
    Vertex Holdings
    Surveyor Capital
  • Series A

    $150,000,000

    Series A Investors

    UBS Oncology Impact Fund
    Redmile Group
    Samsara BioCapital
    EcoR1 Capital
Funding info provided by Diffbot.